Switch theme
Sign up to access all valuation multiples
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
2005
65
Last FY Revenue n/a
LTM EBITDA -$104M
-$9.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Larimar Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$104M.
In the most recent fiscal year, Larimar Therapeutics achieved revenue of n/a and an EBITDA of -$90.6M.
Larimar Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Larimar Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$104M | XXX | -$90.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$109M | XXX | -$90.9M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$100M | XXX | -$80.6M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Larimar Therapeutics's stock price is $2.
Larimar Therapeutics has current market cap of $143M, and EV of -$9.2M.
See Larimar Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$9.2M | $143M | XXX | XXX | XXX | XXX | $-1.57 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Larimar Therapeutics has market cap of $143M and EV of -$9.2M.
Larimar Therapeutics's trades at n/a EV/Revenue multiple, and 0.1x EV/EBITDA.
Equity research analysts estimate Larimar Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Larimar Therapeutics has a P/E ratio of -1.4x.
See valuation multiples for Larimar Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $143M | XXX | $143M | XXX | XXX | XXX |
| EV (current) | -$9.2M | XXX | -$9.2M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBIT | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.4x | XXX | -1.8x | XXX | XXX | XXX |
| EV/FCF | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLarimar Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.4M for the same period.
Larimar Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Larimar Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Larimar Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 30% | XXX | 77% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Larimar Therapeutics acquired XXX companies to date.
Last acquisition by Larimar Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Larimar Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Larimar Therapeutics founded? | Larimar Therapeutics was founded in 2005. |
| Where is Larimar Therapeutics headquartered? | Larimar Therapeutics is headquartered in United States of America. |
| How many employees does Larimar Therapeutics have? | As of today, Larimar Therapeutics has 65 employees. |
| Who is the CEO of Larimar Therapeutics? | Larimar Therapeutics's CEO is Dr. Carole Ben-Maimon, M.D.. |
| Is Larimar Therapeutics publicy listed? | Yes, Larimar Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Larimar Therapeutics? | Larimar Therapeutics trades under LRMR ticker. |
| When did Larimar Therapeutics go public? | Larimar Therapeutics went public in 2020. |
| Who are competitors of Larimar Therapeutics? | Similar companies to Larimar Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Larimar Therapeutics? | Larimar Therapeutics's current market cap is $143M |
| Is Larimar Therapeutics profitable? | Yes, Larimar Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Larimar Therapeutics? | Larimar Therapeutics's last 12 months EBITDA is -$104M. |
| What is the current EV/EBITDA multiple of Larimar Therapeutics? | Current EBITDA multiple of Larimar Therapeutics is 0.1x. |
| What is the current FCF of Larimar Therapeutics? | Larimar Therapeutics's last 12 months FCF is -$90.4M. |
| What is the current EV/FCF multiple of Larimar Therapeutics? | Current FCF multiple of Larimar Therapeutics is 0.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
